Scarica l'app Stockscreener
417.21
1.23%
-5.18
Dopo l'orario di chiusura:
417.05
-0.16
-0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$422.39
Aprire:
$418.02
Volume 24 ore:
1.32M
Relative Volume:
0.73
Capitalizzazione di mercato:
$106.97B
Reddito:
$11.39B
Utile/perdita netta:
$3.64B
Rapporto P/E:
29.82
EPS:
13.9904
Flusso di cassa netto:
$3.50B
1 W Prestazione:
-2.16%
1M Prestazione:
+5.54%
6M Prestazione:
-17.14%
1 anno Prestazione:
-11.30%
Intervallo 1D:
$415.77
$422.98
Intervallo di 1 settimana:
$415.77
$432.76
Portata 52W:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Confronta VRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
417.21 | 108.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
652.91 | 69.37B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.59 | 62.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
821.97 | 51.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.95 | 34.94B | 398.11M | -1.03B | -868.57M | -5.7032 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Published on: 2025-10-29 04:32:30 - newser.com
Is Vertex Pharmaceuticals Incorporated (VX1) stock a buy on weaknessJuly 2025 Big Picture & High Accuracy Trade Signal Alerts - newser.com
Can machine learning forecast Vertex Pharmaceuticals Incorporated recoveryEntry Point & High Conviction Buy Zone Picks - newser.com
Will Vertex Pharmaceuticals Incorporated benefit from macro trendsPortfolio Gains Summary & Risk Managed Investment Entry Signals - newser.com
Visual analytics tools that track Vertex Pharmaceuticals Incorporated performance2025 Pullback Review & Capital Efficient Trade Techniques - newser.com
H.C. Wainwright Reiterates a Buy Rating on Vertex Pharmaceuticals (VRTX) - Insider Monkey
Vertex Pharmaceuticals Stock Rises 8.9% as Pipeline Progress Renews Valuation Debate - Yahoo Finance
Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings (VRTX) - Seeking Alpha
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - Yahoo Finance
Is Vertex Pharmaceuticals Incorporated stock a safe investment in uncertain marketsPortfolio Gains Summary & Free Safe Entry Trade Signal Reports - newser.com
Real time pattern detection on Vertex Pharmaceuticals Incorporated stockTrade Risk Assessment & Daily Entry Point Trade Alerts - newser.com
How big funds are accumulating Vertex Pharmaceuticals Incorporated (VX1) stockEarnings Recap Report & AI Driven Stock Reports - newser.com
Published on: 2025-10-28 05:03:31 - newser.com
Momentum divergence signals in Vertex Pharmaceuticals Incorporated chartPortfolio Update Summary & Pattern Based Trade Signal System - newser.com
Will Vertex Pharmaceuticals Incorporated bounce back from current supportDay Trade & Free Risk Controlled Daily Trade Plans - newser.com
Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potentialQuarterly Investment Review & Daily Oversold Bounce Ideas - newser.com
Using data tools to time your Vertex Pharmaceuticals Incorporated exitForecast Cut & Weekly Consistent Profit Watchlists - newser.com
Long term hold vs stop loss in Vertex Pharmaceuticals IncorporatedWeekly Profit Recap & Weekly Watchlist of Top Performers - newser.com
How Vertex Pharmaceuticals Incorporated (VX1) stock compares with top peersMarket Activity Recap & Entry Point Confirmation Signals - newser.com
Vertex Pharmaceuticals Advances VX-407 Study for ADPKD - TipRanks
Vertex Pharmaceuticals Advances Pain Management with Suzetrigine Study - TipRanks
Vertex Pharmaceuticals’ VX-993 Study: A Potential Game-Changer for Diabetic Neuropathy - TipRanks
Vertex Pharmaceuticals’ Inaxaplin Study: A Potential Game-Changer in Kidney Disease Treatment - TipRanks
Vertex Pharmaceuticals Advances in DPN Treatment with Suzetrigine Study - TipRanks
Vertex Pharmaceuticals’ VX-828 Study: A New Hope for Cystic Fibrosis Treatment - TipRanks
Vertex Pharmaceuticals Advances Genetic Research in ADPKD with New Study - TipRanks
Vertex Pharmaceuticals Advances Phase 3 Study on Suzetrigine for Diabetic Neuropathy Pain - TipRanks
Vertex Pharmaceuticals’ Suzetrigine Study: A New Frontier in Pain Management - TipRanks
Vertex and Moderna’s VX-522 Study: A Potential Breakthrough in Cystic Fibrosis Treatment - TipRanks
Vertex Pharmaceuticals Advances in Kidney Disease Treatment with VX-147 Study - TipRanks
Vertex Pharmaceuticals: Pioneering New Treatments for Kidney Disorder - TipRanks
Vertex Pharmaceuticals’ VX-880 Study: A Potential Game-Changer for Type 1 Diabetes with Kidney Transplant - TipRanks
Vertex Pharmaceuticals Advances VX-670 Study for Myotonic Dystrophy Type I - TipRanks
Vertex to Participate in the UBS Global Healthcare Conference on November 11 - Business Wire
Vertex Pharmaceuticals’ VX-407 Study: A Potential Game-Changer in Oral Contraceptive Pharmacokinetics - TipRanks
Vertex Pharmaceuticals’ Promising Cystic Fibrosis Study: A Potential Game-Changer - TipRanks
Vertex’s VX-880 Study: A Potential Game-Changer for Type 1 Diabetes - TipRanks
Vertex Pharmaceuticals Advances Cystic Fibrosis Treatment with New Pediatric Study - TipRanks
Vertex Pharmaceuticals Advances Sickle Cell Disease Treatment with Exa-cel Study - TipRanks
Vertex Pharmaceuticals Advances VX-670 Study for Myotonic Dystrophy Type 1 - TipRanks
Vertex Pharmaceuticals Advances with Promising CRISPR Gene-Editing Study - TipRanks
Will Vertex Pharmaceuticals Incorporated stock beat EPS estimates2025 Price Momentum & Trade Opportunity Analysis - Fundação Cultural do Pará
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? - sharewise.com
Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030 - The Globe and Mail
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
1.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):